**Resources for Duchenne Muscular Dystrophy**:

*Supplement to September 2023 PAGC newsletter article*

* Invitae offers a no-cost testing option for either DMD or a larger neuromuscular gene panel. The panel is sponsored by the Muscular Dystrophy Association (MDA) and Sarepta Therapeutics. Post-test genetic counseling for positive or VUS results is available at no charge through Genome Medical

<https://www.invitae.com/us/sponsored-testing/detect-mdys>

* Parent Project Muscular Dystrophy (**PPMD**) maintains a database of DMD variants. They offer no-cost testing for CPK, DMD gene analysis with reflex to a larger neuromuscular panel, and more recently RNA-seq on muscle tissue. They also offer no-cost testing for suspected carriers of DMD. Genetic counseling is also offered through PPMD.

<https://www.parentprojectmd.org/about-duchenne/decode-duchenne/>

* MDA Fact Sheet about DMD

<https://www.mda.org/disease/duchenne-muscular-dystrophy>

* PPMD Exon skipping tool to determine treatment eligibility

<https://www.parentprojectmd.org/wp-content/exondeletiontool/>

* PPMD standards of care

<https://www.parentprojectmd.org/care/care-guidelines/>

* PPMD Webinar about advocating for current therapies <https://www.parentprojectmd.org/watch-advocating-for-access-navigating-approved-therapies-in-duchenne-webinar-recording/>
* Review of DMD-related gene therapy

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673537/>

* FDA News Release

<https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy>

* FDA insert with safety and efficacy information

<https://www.fda.gov/media/169679/download#page12>